Brand Name: Imatib
Generic Name: Imatinib mesylate
Manufacturer: Cipla
Dosage Form: Tablets
Strength: 100mg and 400mg
Composition: Imatinib mesylate
Indication: Blood cancer
Packaging: 10 tablets in a strip
Storage: Store at room temperature
OVERVIEW
Imatib (Imatinib mesylate) tablet is used in the treatment of blood cancer. This medicine belongs
to a class of drugs known as tyrosine kinase inhibitors. The Imatib tablet works by stopping the
growth of cancer cells and also prevents the multiplication of cancerous cells. It is important to
take this medicine as prescribed by your doctor. The recommended dose of Imatib tablet is
decided by a doctor according to your previous medical condition and response to the
treatment. Regular monitoring of blood cell count and liver function is required while having
treatment with this medicine. Do not stop the use of Imatib tablets without consulting with your
doctor. If you experience any signs and symptoms while receiving this medicine, inform your
doctor immediately.
Pharmacodynamics
Imatinib Mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine
kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome
abnormality in CML. It inhibits proliferation and induces apoptosis in BCR-ABL-positive cell lines
as well as fresh leukemic cells from Philadelphia chromosome-positive chronic myeloid
leukemia.
Interactions
Imatib tablets can interact with other medications and it may increase the risk for side effects.
Don’t forget to disclose and discuss your previous medical history with the doctor.
Medicine Interactions
● Baricitinib
● Carbamazepine
● Warfarin
● Pimozide
● Etanercept
● Leflunomide
Disease Interactions
● Bone marrow suppression
● Fluid retention
● Liver impairment
● Cardiovascular disease
● Kidney impairment
Alcohol Interaction
● Interaction with alcohol is unknown. Please consult your doctor before consuming
alcohol.
Contraindications
● Do not take this medicine if you are allergic to Imatinib mesylate.
● Imatib (Imatinib mesylate) medicine is not recommended in patients known to be
hypersensitive.


